Orelabrutinib API is a small-molecule pharmaceutical compound developed as a highly selective, covalent inhibitor of Bruton’s tyrosine kinase (BTK). It is also known by the development code ICP-022 / ICP022. PubChem identifies Orelabrutinib with CAS No. 1655504-04-3, molecular formula C26H25N3O3, and molecular weight 427.5 g/mol.
Orelabrutinib belongs to the class of targeted kinase inhibitors and is associated with therapeutic development in B-cell malignancies. BTK is an important signaling protein in B-cell receptor pathways, making it an important molecular target for diseases involving abnormal B-cell proliferation and survival. Orelabrutinib was designed as a highly selective BTK inhibitor with covalent target engagement.
These chemical identifiers are supported by the current PubChem record.
Orelabrutinib has a molecular formula of C26H25N3O3 and molecular weight of 427.5 g/mol. PubChem reports an exact and monoisotopic mass of 427.18959167 Da. Its calculated XLogP3-AA is 3.6, while its hydrogen-bond donor and acceptor counts are 1 and 4, respectively. It contains 6 rotatable bonds, with a topological polar surface area of 85.5 Ų.
The systematic chemical name describes the compound as a substituted pyridine carboxamide containing a phenoxyphenyl group and an acryloyl-substituted piperidine ring. The acrylamide functionality is particularly relevant to its covalent interaction with BTK.
Orelabrutinib is primarily associated with targeted treatment strategies involving BTK-dependent B-cell signaling. BTK inhibition can interfere with B-cell receptor signaling and downstream pathways involved in cellular proliferation, activation and survival.
Potential pharmaceutical and research applications include:
PubChem describes Orelabrutinib as a small-molecule BTK inhibitor with potential antineoplastic activity and notes its mechanism through inhibition of BTK-mediated signaling.
For pharmaceutical API development, Orelabrutinib should be characterized using validated analytical procedures covering identity, assay, related substances, residual solvents, water content, elemental impurities and other applicable critical quality attributes.
Because a publicly accessible official pharmacopoeial monograph with a complete numerical API release specification was not identified, numerical acceptance limits should not be invented or presented as universal pharmacopoeial limits. Where authoritative numerical data are available, they are provided in the Detailed Specifications section below.
USP guidance recognizes impurities as important critical quality attributes for drug substances and describes the need for appropriate control of process-related impurities and degradation products.
A pharmaceutical-grade Orelabrutinib API program generally requires appropriate raw-material controls, validated manufacturing processes, in-process controls and finished-API testing. Analytical characterization may include HPLC/UPLC, LC-MS, NMR, IR, XRPD, GC, Karl Fischer analysis and elemental analysis depending on the specification and regulatory requirements.
Important documentation may include:
The distinction between verified chemical identity information and manufacturer-specific release specifications is important when preparing a CMS/API product page.
Orelabrutinib is particularly relevant to pharmaceutical companies and research organizations working on targeted therapies involving BTK. Its defined chemical structure, molecular weight and established development identity make it suitable for analytical reference, formulation research and pharmaceutical development applications.
The PubChem record currently lists Orelabrutinib, ICP-022 and ICP022 as synonyms and confirms 1655504-04-3 as its CAS-associated identifier.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.2% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 0.5% |